Member Info for Laura2022

Likely that the maximum proceeds that may be realisable from the sale of the Group's remaining assets will be less than the liabilities of the Group. In these circumstances, the Company would cease trading and would be placed into administration

Every fact we present he cant argue with

Hence his nonsensical outburst and faux alliances

"Both myself and Trout are long term FAB and PYC investors/traders"

And every lie/ untruth youve posted has been dis proved

Hence why you just go away event few days as you cant compete with intellectual and factual arguments

Just go away

Jaari888

You don't hold PYC

Also , while you're at it with your nonsense

FAB and PYC have BOTH had 3 placings since 2023, therefore 1 a year, thats what AIM is for?, to allow companies 5p access funds till breakeven and cashflows ?

Any comments Jaari888???, or are you going to slip into the ether again when inconvenient facts spoil your false narrative

Topshares

It's why I see about 20-30 green boxes a day

They are sad , pathetic and filtered

It's easy ignoring them

All 3 of these are currently LOSS making and PRE profit so really not sure what your point is

SCE is also heavily loss making and miles from profit but youve slapped a 5-+0p valuation !!

Comparisons(basic and nead to adjust for cash /losses for each ) in bio tech sphere as of August 2025

APTA £14mlnncap and £1.2mln full year revs( = x 12 annual rev)

FAB £17 mln and £1.7mln full year ( x 10)

PYC £1.4mln and £0.85mln full year ( x less than 2 )

All contracts whether here or FAB are designed to get to the point of breakeven and profitability

FAB is also loss making therefore their contracts are currently not profitable

PYC also develops IP and has valuable IP

Please go away with your obsessed disruption

Here's another from the bottom of the SAME RNS

remain encouraged by our longer-term outlook, having witnessed first-hand the recently improved client engagement. In particular, the ongoing contract discussions which, if successful, would prove materially significant and fundamentally game-changing for RC Fornax's market positioning."

Stick to catching a falling knife on TTG and trolling

How is TTG going ?

What was your ID before re joining?

Model-informed drug development (MIDD) methods play critical role to ensure development of efficacious, and safe individualized therapies. The application of artificial intelligence/machine learning (AI/ML) within the field of drug development has exponentially expanded. Integrating AI/ML into traditional pharmacometrics approaches or using AI/ML as a stand-alone tool has the potential to optimize dosing strategies, inform clinical trial designs, and enhance robustness of quantitative assessments of drug efficacy and safety

Mark Davies of PYC has posted 3 good links recently, all of which capture the momentum in these fields of Ai/ml ( artificial intelligence/machine learning, as well as PK modelling and MDD

All of which are now proven specialisms of PYC

Physiomics plc

1,957 followers

1w Edited

AI is everywhere.

Our team has pulled together three quick reads that have piqued their interest this month – from the intersection of AI/ML with MIDD, to the tangible cost/time savings that MIDD can provide across an entire development portfolio.

🗨️ On the increasing commentary around AI/ML across the drug development space, Dr Mark Davies adds:

“I’m sure we will continue to see new approaches develop, and the hope is that a collaborative mindset as to how these techniques make the art of modelling smoother will win through.”

Explore our July picks below 👇

RCFX large trades

Pentwater Asset Mgmt in June went below 3%, which on 57mln shares in issue is less than 1.5mln, they have been selling in small amounts during June and July and then ladt week was the highest volume week since their Tr1 on 4th June .

Sells 75k, 350k, 250k, 250k (Fri) 70k and 70.8k buy (fri)

Sell 100k 11.5k (Thurs)

YesN the share breako8t has been several days in the making and Fridays close was the highest of the week and a consecutive blue close

HH

Hopefully there motives and hypocrisy is evident and e can talk RCFX

So Satan

How about you worry about TTG which has fallen 30% since you bought and claiming VLX will go for a takeover (ramp?)

And I'll worry about my investment in RCFX

Hopefully we won't hear any more from you in your latest ID)

Have.a good weekend

Morning Trench123

And now a whole varied opportunity

From TU

"Expansion into new therapeutic areas: 50% of projects delivered in FY25 were in therapeutic areas outside oncology, compared to an average of 5% over the previous three years"

This was mentioned in June

Would hope to hear further news in Q3/early Q4

Expansion of collaboration

Physiomics and DoseMe have recently signed non-binding Heads of Terms with the intention of expanding their partnership beyond the Company's current personalised dosing software. This agreement defines terms across four areas of collaboration:

· development and commercialisation of novel dosing software tools originating from Physiomics;

· development and commercialisation of novel dosing software tools originating from DoseMe or its clients;

· provision of consultancy services by the Company to DoseMe; and

· co-development of clinical trial dosing software in support of biopharmaceutical clients.

The two parties are actively working to identify potential projects falling under these umbrella categories and further announcements on this will be made when appropriate.

Goes without saying, have a lovely weekend and would be pleasant from Monday onwards where genuine investors seek for the company to do well and acknowledge the progress made by the new CEO ( as laid bare in the trading ahead of expectations) and , like all other companies on AIM , understand that most are loss making still

What's pleasing to see for bio techs is that "service providers " for want of a better word are actually doing rather well this last 6mths ( APTA FAB PYC) and are all generating high revenues than 2024